{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tirzepatide","verification":{"valid":true,"entries":9,"head":"ad6e91b274078e283ee4632a73f15cb4d608761221c5453b2edbd0d2c5d627cd"},"count":9,"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/35658024/","title":"Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)","quote":"The mean percentage change in weight at week 72 was -15.0% with 5-mg weekly doses of tirzepatide, -19.5% with 10-mg doses, and -20.9% with 15-mg doses and -3.1% with placebo. 50% and 57% of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% in the placebo group.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"genesis","hash":"1e94328f2e7486a45c3c805477777f3f9b694dc670da7cfb8d110f73ba5674e4"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37385275/","title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)","quote":"Least-squares mean change in bodyweight at week 72 with tirzepatide 10 mg and 15 mg was -12.8% and -14.7%, respectively, and -3.2% with placebo. More participants treated with tirzepatide versus placebo met bodyweight reduction thresholds of 5% or higher (79-83% vs 32%).","accessed_at":"2026-08-04T22:29:23.593Z","prev":"1e94328f2e7486a45c3c805477777f3f9b694dc670da7cfb8d110f73ba5674e4","hash":"400c6f05ba99f2ff0685b83a8d279118792339dc05e8d52ab28a25a0917795f1"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38912654/","title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)","quote":"In trial 1, the mean change in AHI at week 52 was -25.3 events per hour with tirzepatide and -5.3 events per hour with placebo. In trial 2, the mean change was -29.3 events per hour with tirzepatide and -5.5 with placebo. Tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"400c6f05ba99f2ff0685b83a8d279118792339dc05e8d52ab28a25a0917795f1","hash":"0f95ebcc5a6e31017cebe112affe436ba2ad1088437884ce11996694cb5e2f7e"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42119587/","title":"Tirzepatide for maintenance of bodyweight reduction (SURMOUNT-MAINTAIN)","quote":"The estimated percent change in bodyweight from baseline to week 112 was -21.9% with the maximum tolerated dose, -16.6% with 5 mg tirzepatide, versus -9.9% with placebo (p<0.0001 for all comparisons).","accessed_at":"2026-08-04T22:29:23.593Z","prev":"0f95ebcc5a6e31017cebe112affe436ba2ad1088437884ce11996694cb5e2f7e","hash":"0f160ba2dde6e73ed0b9f7764bf3082043a6b113fa16ed47daabd956de6d6cf4"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42412744/","title":"Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses","quote":"These post-hoc analyses evaluated patient-reported outcome measures and objective assessments, considering participants' baseline characterization of fatigue, sleepiness, snoring, and sleep quality.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"0f160ba2dde6e73ed0b9f7764bf3082043a6b113fa16ed47daabd956de6d6cf4","hash":"c2053663f28d840bf54be950e6049ddccdedd51abdf169015562f97dd025acd0"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42348366/","title":"Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials","quote":"We aimed to assess weight reduction, cardiometabolic risk parameters, tolerability and hypoglycaemia according to early body weight response to tirzepatide.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"c2053663f28d840bf54be950e6049ddccdedd51abdf169015562f97dd025acd0","hash":"c13c8d3162ee1a01fe851df618a6a313c0a707d920e8b339a128a3b5b24fd8a2"},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42233927/","title":"Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis","quote":"The purpose of this study was to evaluate the association of tirzepatide compared to placebo on biomarkers that reflect inflammation (high-sensitivity C-reactive protein, interleukin-6, fibrinogen, leukocyte count).","accessed_at":"2026-08-04T22:29:23.593Z","prev":"c13c8d3162ee1a01fe851df618a6a313c0a707d920e8b339a128a3b5b24fd8a2","hash":"aade3bb298be4fb4abd618d76841d23a1125978cdf3f9c4971f1ea4736a947b9"},{"id":"s8","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/42487213/","title":"Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis","quote":"Given ethnic differences in obesity phenotype and cardiometabolic risk, this systematic review and meta-analysis compared tirzepatide's efficacy and safety between Asian and non-Asian adults without diabetes.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"aade3bb298be4fb4abd618d76841d23a1125978cdf3f9c4971f1ea4736a947b9","hash":"006385f876046d1638c7f07f408e53ee389217cfaa0d7938e29321a16be1dcf4"},{"id":"s9","type":"clinical_trial","url":"https://pubmed.ncbi.nlm.nih.gov/42297568/","title":"SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity","quote":"A 5-year, phase 4, multicenter, open-label, pragmatic randomized clinical trial... The study will enroll approximately 3000 participants.","accessed_at":"2026-08-04T22:29:23.593Z","prev":"006385f876046d1638c7f07f408e53ee389217cfaa0d7938e29321a16be1dcf4","hash":"ad6e91b274078e283ee4632a73f15cb4d608761221c5453b2edbd0d2c5d627cd"}]}